Clinical Trials Search Results

Search for

Showing 1-3 of 3

Sorted By:

Previous Next

BGB-21447-101: A Phase 1/1b Open-Label Dose-Escalation and Dose-Optimization Study of Bcl-2 Inhibitor BGB-21447 in Patients With Mature B-Cell Malignancies {enrollment closed 12/22/25}
A Phase 1/1b Open-Label Dose-Escalation and Dose-Optimization Study of Bcl-2 Inhibitor BGB-21447 in Patients With Mature B-Cell Malignancies
KT-US-471-0140: Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification Axicabtagene Ciloleucel
Provide access to axicabtagene ciloleucel for patients with a disease approved for treatment with axicabtagene ciloleucel, out of specification for commercial release.
KT-US-472-0141: Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification Brexucabtagene Autoleucel
Provide access to brexucabtagene autoleucel for patients with a disease approved for treatment, that is otherwise out of specification for commercial release.

Previous Next